Physician profile
Laura Helmly
NPI 1376939207
$849.87
in general payments reported to CMS, 2019-2025
17 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $178 · 2023: $317 · 2024: $244 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $223.75 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $120.79 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $75.51 | 2023-2024 | Farxiga, Breztri |
| Lilly USA, LLC | $70.98 | 2022-2024 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $66.36 | 2023-2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $46.58 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $35.96 | 2023-2024 | Eliquis |
| Dynavax Technologies Corporation | $32.63 | 2025 | Heplisav-B |
| Glaxosmithkline, LLC. | $32.42 | 2022-2025 | Shingrix, Arexvy |
| Amgen INC. | $23.25 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.56 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.17 | 2023 | Rexulti |
| Philips North America LLC | $18.01 | 2024 | (5050) Extended Holter |
| Janssen Scientific Affairs, LLC | $17.67 | 2023 | Xarelto |
| Abbvie INC. | $16.14 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.86 | 2022 | |
| Kyowa Kirin, INC. | $14.23 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Helmly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.